← Leaderboards
Tyler Martin
Adjuvance Technologies, Inc.
$1,471,319
Attributed
$1,471,319
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2019–20$2M$1.5M$1M$500K$0
'19
'20
Funding mix
By agency
NIH$1,471,319 · 1
By mechanism
N43$1,471,319 · 1
Top collaborators
No co-investigators on record.
Most similar at Adjuvance Technologies, Inc.
Same institution · by research overlap
- Philip Livingston$223,002
Others in their field
Other Emerging Leaders on “Adjuvant”
- Ted Ross · University Of Georgia$68,763,143
- Jay Evans · University Of Montana$43,101,450
- Valerie Fremont · Quality Biological, Inc.$19,261,930
- Aaron Esser-Kahn · University Of Chicago$13,698,058
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$10,000,000
- Garcia-Sastre Adolfo · Icahn School Of Medicine At Mount Sinai$8,560,974
Research focus
AdjuvantAntibody ResponseAntigensCommunicable DiseasesDoseFluzoneHemagglutininImmunogenicImmunogenicityImmunologic AdjuvantsInfluenza A Virus, H1n1 SubtypeInfluenza Virus VaccinePreclinical DevelopmentSaponinsSavingsSerologicalT Cell ResponseVaccines
Grant awards (2)
Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine$44,297
N43 · FY2020 · AI · contact PI
Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine$1,427,022
N43 · FY2019 · AI · contact PI